Amlodipine News and Research

RSS

Single-tablet combination of atorvastatin and amlodipine for high blood pressure effective

Adults with high blood pressure and additional risk factors for heart disease may benefit more from taking one tablet rather than two, if their current treatment combines the lipid-lowering medication atorvastatin with the blood pressure-lowering medication amlodipine, researchers reported at the American Heart Association's 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

16 May 2007

FDA confirms Mylan's status as only approved ANDA for all strengths of Amlodipine Besylate tablets

Mylan Laboratories has announced that the U.S. Food and Drug Administration (FDA) has confirmed Mylan's current status as the only approved ANDA for all strengths of Amlodipine Besylate Tablets.

20 Apr 2007

U.S. District Court grants Mylan extension for consideration of Amlodipine Besylate exclusivity

Mylan Laboratories has announced that the U.S. District Court for the District of Columbia has extended the deadlines pertaining to Mylan's request for a temporary restraining order in its lawsuit seeking to stop the U.S. Food and Drug Administration (FDA) from approving any other Amlodipine Besylate abbreviated new drug applications (ANDAs).

11 Apr 2007

Pfizer wins Norvasc patent challenge by Mylan

Pfizer said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the company's U.S. patent covering the active ingredient in Norvasc

27 Feb 2007

Study shows Diovan reduced urinary protein excretion in patients with type 2 diabetes and high blood pressure

In patients with high blood pressure and type 2 diabetes, the blood pressure-lowering medication Diovan (valsartan) significantly reduced urinary protein excretion, with high doses providing the greatest sustained reduction , according to data presented at the Amer ican Heart Association's (AHA) Annual Scientific Sessions.

13 Nov 2006

Diabetes risk down three times with newer hypertension drugs

According to researchers patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills.

7 Sep 2006

One of the largest Japanese cardiovascular trials confirms angiotensin receptor blockade protects people who have a wide range of cardiovascular diseases

The first controlled large-scale intervention trial of angiotensin receptor blockade in Japanese patients has confirmed that the cardiovascular protective effects of the drug valsartan is greater than to those seen with other therapies giving the same level of blood pressure control.

5 Sep 2006

Pfizer wins Norvasc patent challenge

Pfizer has said that a federal court in the Middle District of North Carolina has upheld the company's U.S. patent covering amlodipine besylate, the active ingredient in Norvasc, the world's most-prescribed branded medicine for treating hypertension.

4 Sep 2006

Blood pressure near the heart is more predictive of cardiovascular outcomes than blood pressure measured in the arm

Results from a new study show that amlodipine-based (calcium channel blocker) treatment is much more effective at reducing blood pressure near the heart than a conventional atenolol-based (beta blocker) regimen.

14 Nov 2005

Norvasc better than beta blockers for lowering blood pressure

According to a study presented at a meeting of the American Heart Association, Norvasc, was more effective at reducing blood pressure near the heart than standard, older treatments such as beta blockers.

14 Nov 2005

Strokes and heart attacks can be prevented in people with high blood pressure

Most strokes and heart attacks in people with high blood pressure can be abolished by simply combining effective, modern blood pressure lowering drugs with treatment to reduce cholesterol.

6 Sep 2005

New blood pressure-lowering drugs reduce stroke risk by 50%

According to researchers the new types of blood pressure-lowering drugs are more effective in preventing strokes and heart attacks and save even more lives.

5 Sep 2005

Diuretics work better than newer and more costly medicines for diabetics with high blood pressure

Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

28 Jun 2005

A drug that controls blood pressure and reduces heart risk also appears to protect against diabetes

In new results from the VALUE trial that pitted the drug valsartan against another blood pressure drug, amlodipine, the patients taking valsartan were found to have a 23 percent lower risk of developing diabetes during the four or more years of the study.

18 May 2005

Blood pressure treatment could cut risk of strokes and heart attacks

A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent according to the preliminary results of a major international trial announced at the American College of Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.

8 Mar 2005

Excellent news for the many people who suffer from high blood pressure

An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.

8 Dec 2004

Startling new blood pressure findings - atherosclerosis slowed

A new study led by The Cleveland Clinic shows that giving blood pressure lowering medication to heart disease patients with a “normal” blood pressure dramatically reduces risk of adverse cardiac events and slows disease progression.

16 Nov 2004

Calcium channel blocker reduces adverse cardiovascular events

The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.

10 Nov 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

Trial sparks debate over treatment of diabetic hypertensives

A major new international study published in the Journal of Hypertension has challenged traditional thinking by revealing that the thiazide-like diuretic indapamide SR (Natrilix SR) has equivalent efficacy to enalapril in reducing microalbuminuria (MA) in patients with type 2 diabetes.

22 Jul 2004